Forefront Analytics’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Forefront Analytics’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,723	Closed	-$46.3K	–	77
2023 Q1	$46.3K	Buy	1,723 +1,310	+317%	+$60.9K	0.02%	74
2022 Q4	$14.6K	Buy	+413	New	+$49.6K	0.01%	75
2022 Q3	–	Sell	-384	Closed	-$73K	–	70
2022 Q2	$73K	Buy	384 +23	+6%	+$4.64K	0.04%	55
2022 Q1	$87K	Buy	361 +16	+5%	+$2.53K	0.03%	64
2021 Q4	$58K	Buy	345 +9	+3%	+$1.74K	0.02%	62
2021 Q3	$68K	Buy	336 +2	+0.6%	+$476	0.02%	64
2021 Q2	$82K	Sell	334 -25	-7%	-$6.24K	0.03%	63
2021 Q1	$97K	Buy	+359	New	+$113K	0.04%	64

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Forefront Analytics's EIGR Position: Q2 2023 in Review

Forefront Analytics sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 1,723 shares — an estimated $46.3K sold.

Forefront Analytics first reported a position in EIGR in Q1 2021 and held it in 8 quarters. The position peaked at $97K in Q1 2021. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

Forefront Analytics reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Forefront Analytics sold 1,723 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $46.3K.
Forefront Analytics first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2021 and held it in 8 quarters.
Forefront Analytics's Eiger BioPharmaceuticals, Inc. position peaked at $97K in Q1 2021.
66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Forefront Analytics's 13F filing for Q2 2023, filed 11 Aug 2023.